Account wins from the 04/28/06 News Brief

Share this article:
The Navicor Group, an inVentiv Health company and a full-service advertising agency that focuses exclusively on the areas of oncology and immunology, has been named agency of record for Hepsera (adefovir dipivoxil), an orally administered prescription medicine for the treatment of chronic hepatitis B. Hepsera was developed by Gilead Sciences. The drug was approved by the FDA in September 2002. The Navicor Group’s assignment includes the development of strategic and creative marketing communications for the product.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.